Published in Hepatology on February 01, 2010
Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol (2010) 1.34
Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications. Expert Rev Gastroenterol Hepatol (2011) 1.22
Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol (2012) 1.21
Association of serum adipocyte-specific Fatty Acid binding protein with Fatty liver index as a predictive indicator of nonalcoholic Fatty liver disease. Endocrinol Metab (Seoul) (2013) 0.86
Non-invasive score identifies ultrasonography-diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA. BMC Med (2014) 0.84
Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol (2015) 0.80
Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. Dig Dis Sci (2015) 0.77
A preliminary investigation on the possible association between diminished copper availability and non-alcoholic fatty liver disease in epileptic patients treated with valproic acid. Ups J Med Sci (2010) 0.77
Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Biomed Res Int (2017) 0.75
Pathological characterization and morphometric analysis of hepatic lesions in SHRSP5/Dmcr, an experimental non-alcoholic steatohepatitis model, induced by high-fat and high-cholesterol diet. Int J Exp Pathol (2016) 0.75
Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology (2009) 3.67
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med (2010) 4.14
Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology (2002) 3.29
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res (2008) 2.77
A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology (2010) 2.67
Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes. Annu Rev Med (2011) 2.59
Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology (2003) 2.44
Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care (2010) 2.22
Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care (2007) 2.02
A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med (2011) 2.01
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab (2005) 1.73
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology (2009) 1.71
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol (2008) 1.69
Obstructive sleep apnea syndrome affects liver histology and inflammatory cell activation in pediatric nonalcoholic fatty liver disease, regardless of obesity/insulin resistance. Am J Respir Crit Care Med (2014) 1.60
Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. J Gen Intern Med (2007) 1.53
High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. J Hypertens (2009) 1.49
Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol (2010) 1.42
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology (2005) 1.34
Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2005) 1.27
Effect of the monocyte chemoattractant protein-1/CC chemokine receptor 2 system on nephrin expression in streptozotocin-treated mice and human cultured podocytes. Diabetes (2009) 1.25
Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy. Diabetes (2010) 1.21
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res (2012) 1.20
Dietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohort. Am J Clin Nutr (2006) 1.17
p53 Mediates the accelerated onset of senescence of endothelial progenitor cells in diabetes. J Biol Chem (2005) 1.12
Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology (2008) 1.09
Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes (2011) 1.08
Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism. Hepatology (2012) 1.07
Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal (2011) 1.07
Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: a possible implication for oxidative stress. World J Gastroenterol (2005) 1.05
Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH? Hepatology (2007) 1.04
The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern-European population-based cohort. Diabetes Metab Res Rev (2005) 1.03
Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology (2009) 1.02
Obstructive sleep apnea-hypopnea syndrome and nonalcoholic fatty liver disease: emerging evidence and mechanisms. Semin Liver Dis (2012) 1.00
Iron supplementation and gestational diabetes in midpregnancy. Am J Obstet Gynecol (2009) 0.97
Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver. Trends Mol Med (2013) 0.96
Ischemic preconditioning attenuates the oxidant-dependent mechanisms of reperfusion cell damage and death in rat liver. Liver Transpl (2002) 0.92
Prognostic implications for insulin-sensitive and insulin-resistant normal-weight and obese individuals from a population-based cohort. Am J Clin Nutr (2012) 0.92
Prevalence of undiagnosed metabolic syndrome in a population of adult asymptomatic subjects. Diabetes Res Clin Pract (2006) 0.92
Impact of sterol regulatory element-binding factor-1c polymorphism on incidence of nonalcoholic fatty liver disease and on the severity of liver disease and of glucose and lipid dysmetabolism. Am J Clin Nutr (2013) 0.91
Associations of dietary and serum copper with inflammation, oxidative stress, and metabolic variables in adults. J Nutr (2008) 0.91
Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu Rev Med (2010) 0.90
STAT5 activation induced by diabetic LDL depends on LDL glycation and occurs via src kinase activity. Diabetes (2002) 0.90
Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmetabolism. Diabetes (2012) 0.86
Effects of TCF7L2 polymorphisms on glucose values after a lifestyle intervention. Am J Clin Nutr (2009) 0.86
Nitrosative stress predicts the presence and severity of nonalcoholic fatty liver at different stages of the development of insulin resistance and metabolic syndrome: possible role of vitamin A intake. Am J Clin Nutr (2007) 0.86
Mild gestational hyperglycemia, the metabolic syndrome and adverse neonatal outcomes. Acta Obstet Gynecol Scand (2004) 0.86